TY - JOUR T1 - Response of human liver tissue to innate immune stimuli JF - medRxiv DO - 10.1101/2020.12.22.20248755 SP - 2020.12.22.20248755 AU - Xia Wu AU - Jessica B. Roberto AU - Allison Knupp AU - Alexander L. Greninger AU - Camtu D. Truong AU - Nicole Hollingshead AU - Heidi L. Kenerson AU - Marianne Tuefferd AU - Antony Chen AU - Helen Horton AU - Keith R. Jerome AU - Stephen J. Polyak AU - Raymond S. Yeung AU - Ian N. Crispe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/11/2020.12.22.20248755.abstract N2 - Precision-cut human liver slice cultures (PCLS) has become an important alternative immunological platform in preclinical testing. To further evaluate the capacity of PCLS, we investigated the innate immune response to TLR3 agonist (poly-I:C) and TLR4 agonist (LPS) with the normal and pathological liver tissue. Pathological liver tissue was obtained from patients with active chronic HCV infection, and patients with former chronic HCV infection cured by recent Direct-Acting Antiviral (DAA) drug therapy. We found that hepatic innate immunity was not suppressed but enhanced in the HCV-infected tissue, compared with the healthy controls. Furthermore, despite recent HCV elimination, DAA-cured liver tissue manifested ongoing abnormalities in liver immunity. Sustained abnormal immune gene expression in DAA-cured samples were identified from direct ex vivo measurements and with TLR3 and TLR4 stimulation assays. Those genes that were up-regulated in chronic HCV-infected liver tissue were enriched in expression in the liver non-parenchymal cell compartment. These results demonstrated the utility of PCLS in studying the liver pathology and innate immunity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis work did not involve clinical trials.Funding StatementThis work was supported by NIH NIAID R56 grant AI143683; US Department of Defense grant CA150370; Janssen Research and Development; the Seattle Foundation; and the University of Washington.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Liver tissue was obtained under Institutional Review Board protocol #00001852 at University of Washington.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.PCLSprecision-cut liver sliceTLRtoll-like receptorNPCnon-parenchymal cellKCKupffer cellsLSECLiver sinusoidal endothelial cellsHSChepatic stellate cellsHCVhepatitis C virusDAAdirect-acting antiviralISGsinterferon-stimulated genesHCChepatocellular carcinomaICCintrahepatic cholangiocarcinomaSVRsustained virologic response ER -